Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors

The findings of large-scale cardiovascular outcome trials have been demonstrated that sodium-glucose cotransporter 2 inhibitors (iSGLT-2) have shown beneficial cardiovascular effects. In this review proposed mechanisms underlying iSGLT-2-associated cardiovascular benefits have been discussed: haemo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. M. Mkrtumyan, T. N. Markova, N. K. Mishchenko
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2021
Materias:	sodium-glucose cotransporter 2 inhibitors cardiovascular effects ketogenesis sodium/hydrogen exchanger n-terminal pro-b-type natriuretic peptide high-sensitivity troponin i Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/97d2e8917f464f4da6b7cc5a343337ff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:97d2e8917f464f4da6b7cc5a343337ff
record_format	dspace
spelling	oai:doaj.org-article:97d2e8917f464f4da6b7cc5a343337ff2021-11-14T09:00:23ZCardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors2072-03512072-037810.14341/DM12541https://doaj.org/article/97d2e8917f464f4da6b7cc5a343337ff2021-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12541https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The findings of large-scale cardiovascular outcome trials have been demonstrated that sodium-glucose cotransporter 2 inhibitors (iSGLT-2) have shown beneficial cardiovascular effects. In this review proposed mechanisms underlying iSGLT-2-associated cardiovascular benefits have been discussed: haemodynamic and intracellular effects, including metabolic effects and electrolyte changes; and also, the effect on markers of cardiovascular disease (CVD). The hemodynamic effects of SGLT-2 are characterized by reduction of cardiac preload and afterload as a result of osmotic diuresis, a decrease in blood pressure and arterial stiffness. The metabolic effects of this medicine are accompanied by an increase the production of ketone bodies, followed by improving ATP production and myocardial energetics. Also, iSGLT-2 modulate ion transporters (NHE1 and NHE3). A reduction of cytoplasmic sodium and calcium levels and increasing mitochondrial calcium levels in the cardiomyocytes enhances the synthesis of ATP and increases cell viability. Effect of iSGLT-2 on CVD markers showed a decrease in the levels of the N-terminal pro-B-type natriuretic peptide and highly sensitive troponin I in elderly patients with type 2 diabetes mellitus (T2DM). Thus, this class of agents has a multifactorial effect on the functioning of cardiovascular system. Further studies will help to explain the all possible cardioprotective effects of iSGLT-2 in individuals with and without T2DM.A. M. MkrtumyanT. N. MarkovaN. K. MishchenkoEndocrinology Research Centrearticlesodium-glucose cotransporter 2 inhibitorscardiovascular effectsketogenesissodium/hydrogen exchangern-terminal pro-b-type natriuretic peptidehigh-sensitivity troponin iNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 24, Iss 3, Pp 291-299 (2021)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	sodium-glucose cotransporter 2 inhibitors cardiovascular effects ketogenesis sodium/hydrogen exchanger n-terminal pro-b-type natriuretic peptide high-sensitivity troponin i Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	sodium-glucose cotransporter 2 inhibitors cardiovascular effects ketogenesis sodium/hydrogen exchanger n-terminal pro-b-type natriuretic peptide high-sensitivity troponin i Nutritional diseases. Deficiency diseases RC620-627 A. M. Mkrtumyan T. N. Markova N. K. Mishchenko Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
description	The findings of large-scale cardiovascular outcome trials have been demonstrated that sodium-glucose cotransporter 2 inhibitors (iSGLT-2) have shown beneficial cardiovascular effects. In this review proposed mechanisms underlying iSGLT-2-associated cardiovascular benefits have been discussed: haemodynamic and intracellular effects, including metabolic effects and electrolyte changes; and also, the effect on markers of cardiovascular disease (CVD). The hemodynamic effects of SGLT-2 are characterized by reduction of cardiac preload and afterload as a result of osmotic diuresis, a decrease in blood pressure and arterial stiffness. The metabolic effects of this medicine are accompanied by an increase the production of ketone bodies, followed by improving ATP production and myocardial energetics. Also, iSGLT-2 modulate ion transporters (NHE1 and NHE3). A reduction of cytoplasmic sodium and calcium levels and increasing mitochondrial calcium levels in the cardiomyocytes enhances the synthesis of ATP and increases cell viability. Effect of iSGLT-2 on CVD markers showed a decrease in the levels of the N-terminal pro-B-type natriuretic peptide and highly sensitive troponin I in elderly patients with type 2 diabetes mellitus (T2DM). Thus, this class of agents has a multifactorial effect on the functioning of cardiovascular system. Further studies will help to explain the all possible cardioprotective effects of iSGLT-2 in individuals with and without T2DM.
format	article
author	A. M. Mkrtumyan T. N. Markova N. K. Mishchenko
author_facet	A. M. Mkrtumyan T. N. Markova N. K. Mishchenko
author_sort	A. M. Mkrtumyan
title	Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
title_short	Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
title_full	Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
title_fullStr	Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
title_full_unstemmed	Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
title_sort	cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
publisher	Endocrinology Research Centre
publishDate	2021
url	https://doaj.org/article/97d2e8917f464f4da6b7cc5a343337ff
work_keys_str_mv	AT ammkrtumyan cardioprotectivemechanismsofsodiumglucosecotransporter2inhibitors AT tnmarkova cardioprotectivemechanismsofsodiumglucosecotransporter2inhibitors AT nkmishchenko cardioprotectivemechanismsofsodiumglucosecotransporter2inhibitors
_version_	1718429478076547072

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors

Ejemplares similares